title: CD30+ neoplasms of the skin.
abstract: Cutaneous T-cell lymphomas (CTCLs) are subdivided by lesion morphology, behavior, and surface receptors. Mycosis fungoides (MF) and Sézary syndrome (SS) are derived from CD4+ effector or central memory T-cells respectively. MF presents clinically as patches, plaques, or tumors, and SS presents with erythroderma. After MF/SS, the next most common CTCLs are CD30+ lymphoproliferative disorders: self-regressing lymphomatoid papulosis (LyP) or tumors of anaplastic large-cell lymphoma (ALCL), which express high levels of tumor necrosis factor death receptor member 8, also called CD30. Although MF is not considered to be a CD30+ lymphoproliferative disorder, MF may co-exist with LyP lesions, and MF may express CD30, especially in the setting of large-cell transformation. The development of targeted therapy for CD30+ CTCLs will help in understanding the importance of the CD30 death receptor in pathogenesis and will improve treatment options.
authors.affiliation: Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, USA. mduvic@mdanderson.org
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D015415:Biomarkers / Q000032:analysis; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology*; D008232:Lymphoproliferative Disorders / Q000276:immunology* / Q000628:therapy; D009182:Mycosis Fungoides / Q000276:immunology*; D012751:Sezary Syndrome / Q000276:immunology* / Q000628:therapy; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy
chemical_list: D015415:Biomarkers; D017730:Ki-1 Antigen